The Exemption Your CDS Tool Is Standing On Is Under Review

The exemption everyone assumed was permanent

Most hospital compliance leads treat clinical decision support software as settled ground. Under the 21st Century Cures Act, CDS tools that let a clinician independently review the basis of a recommendation generally fall outside FDA’s device definition. That carve-out is why thousands of AI-enabled CDS deployments in US hospitals today were never cleared, never submitted, and never built a device-grade quality file.

That ground just got less stable. The American Hospital Association’s response to FDA’s request for input on the Section 3060 required report shows the agency is actively reconsidering how the CDS exemption works in practice, not just in theory. AHA is asking FDA to permanently adopt the enforcement flexibility that currently lets CDS tools generate a single clinical recommendation without triggering full device review, and to clarify the General Wellness Guidance rather than let ambiguity persist. The alternative on the table, explicitly named in AHA’s letter, is that FDA removes the relevant section altogether, which would eliminate the interpretive buffer providers have relied on (AHA).

Why this splits the AI regulatory landscape

Device-classified AI, the imaging algorithms, the computational pathology tools, the diagnostic panels, already sits inside a maturing regulatory science track. Peer-reviewed work on AI-based software as a medical device in computational pathology and biomarker-driven drug development lays out validation expectations, performance benchmarking, and lifecycle management frameworks that regulators and manufacturers are actively refining together (PMC). That is a track with structure, precedent, and a shared vocabulary.

CDS tools sit in the opposite condition. They are frequently built as Software in a Medical Device or standalone SaMD-adjacent products, developed under internal engineering discipline rather than device design controls, precisely because the exemption says they do not need it (Easy Medical Device). That engineering discipline rarely produces the documentation trail a device submission would require: traceable validation data, defined intended use boundaries, change control history. If FDA narrows or removes the exemption, the gap between what these tools have and what a 510(k) or De Novo file demands will not close quickly.

The decision in front of compliance leaders

The question is not whether your CDS tool is currently exempt. It likely is, today. The question is whether your organization has any evidence trail that would survive scrutiny if that exemption tightens before your next AI-CDS deployment goes live. AHA’s letter is a signal that this is now an active policy conversation, not a settled interpretation.

Practical posture: inventory every CDS tool making clinical recommendations, confirm each one still meets the “single recommendation, independently reviewable basis” test AHA is defending, and start building validation documentation as if device-grade rigor were coming. Waiting for FDA’s final report to start that work means starting it after the deadline that matters has already passed.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that the CDS exemption is under active review and compliance teams should prepare—is coherent and supported by the AHA letter citation, but the piece overstates certainty about FDA’s
Source & Claim Verification	Qwen · local	cleared. The draft generally supports its claims with citations, but some lines lack specific references, particularly in the ‘Why this splits the AI regulatory landscape’ section.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the current FDA CDS exemption landscape under the 21st Century Cures Act and aligns with the regulatory reconsideration signaled by AHA, without conflating EU AI Act,
Technical Accuracy	Llama	cleared. The article is generally technically accurate regarding the regulatory status of clinical decision support tools and the potential implications of changes to the FDA’s exemption policy.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively highlights a potential regulatory shift and its implications, with minimal vendor hype and a clear counterargument presented through the AHA’s position.
Novelty & Non-Duplication	Grok	held. The peg is a routine AHA comment letter defending existing CDS flexibility rather than a concrete FDA move, so the ‘exemption under review’ urgency is oversold and the inventory/documentation advice i
Validation	DeepSeek	cleared. The central claim that FDA is actively reconsidering the CDS exemption is directly validated by the cited AHA letter, which explicitly discusses the agency’s review and the potential removal of the re

Sources cited: 15. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.